Cargando…
Virological and Serological Characterisation of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination Between December 2020 and March 2021
BACKGROUND: Vaccines for coronavirus disease 2019 (COVID-19) are proving to be very effective in preventing severe illness; however, although rare, post-vaccine infections have been reported. The present study focuses on virological and serological features of 94 infections that occurred in Lazio Re...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810639/ https://www.ncbi.nlm.nih.gov/pubmed/35127770 http://dx.doi.org/10.3389/fmed.2021.815870 |
_version_ | 1784644286965350400 |
---|---|
author | Colavita, Francesca Meschi, Silvia Gruber, Cesare Ernesto Maria Rueca, Martina Vairo, Francesco Matusali, Giulia Lapa, Daniele Giombini, Emanuela De Carli, Gabriella Spaziante, Martina Messina, Francesco Bonfiglio, Giulia Carletti, Fabrizio Lalle, Eleonora Fabeni, Lavinia Berno, Giulia Puro, Vincenzo Bartolini, Barbara Di Caro, Antonino Ippolito, Giuseppe Capobianchi, Maria Rosaria Castilletti, Concetta |
author_facet | Colavita, Francesca Meschi, Silvia Gruber, Cesare Ernesto Maria Rueca, Martina Vairo, Francesco Matusali, Giulia Lapa, Daniele Giombini, Emanuela De Carli, Gabriella Spaziante, Martina Messina, Francesco Bonfiglio, Giulia Carletti, Fabrizio Lalle, Eleonora Fabeni, Lavinia Berno, Giulia Puro, Vincenzo Bartolini, Barbara Di Caro, Antonino Ippolito, Giuseppe Capobianchi, Maria Rosaria Castilletti, Concetta |
author_sort | Colavita, Francesca |
collection | PubMed |
description | BACKGROUND: Vaccines for coronavirus disease 2019 (COVID-19) are proving to be very effective in preventing severe illness; however, although rare, post-vaccine infections have been reported. The present study focuses on virological and serological features of 94 infections that occurred in Lazio Region (Central Italy) between 27 December 2020, and 30 March 2021, after one or two doses of mRNA BNT162b2 vaccine. METHODS: We evaluated clinical features, virological (viral load; viral infectiousness; genomic characterisation), and serological (anti-nucleoprotein Ig; anti-Spike RBD IgG; neutralising antibodies, nAb) characteristics of 94 post-vaccine infections at the time of diagnosis. Nasopharyngeal swabs (NPSs) and serum samples were collected in the framework of the surveillance activities on SARS-CoV-2 variants established in Lazio Region (Central Italy) and analysed at the National Institute for Infectious Diseases “L. Spallanzani” in Rome. RESULTS: The majority (92.6%) of the post-vaccine infections showed pauci/asymptomatic or mild clinical course, with symptoms and hospitalisation rate significantly less frequent in patients infected after full vaccination course as compared to patients who received a single dose vaccine. Although differences were not statistically significant, viral loads and isolation rates were lower in NPSs from patients infected after receiving two vaccine doses as compared to patients with one dose. Most cases (84%) had nAb in serum at the time of infection diagnosis, which is a sub-group of vaccinees, were found similarly able to neutralise Alpha and Gamma variants. Asymptomatic individuals showed higher nAb titres as compared to symptomatic cases (median titre: 1:120 vs. 1:40, respectively). Finally, the proportion of post-vaccine infections attributed either to Alpha and Gamma variants was similar to the proportion observed in the contemporary unvaccinated population in the Lazio region, and mutational analysis did not reveal enrichment of a defined set of Spike protein substitutions depending on the vaccination status. CONCLUSION: Our study conducted using real-life data, emphasised the importance of monitoring vaccine breakthrough infections, through the characterisation of virological, immunological, and clinical features associated with these events, in order to tune prevention measures in the next phase of the COVID-19 pandemic. |
format | Online Article Text |
id | pubmed-8810639 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88106392022-02-04 Virological and Serological Characterisation of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination Between December 2020 and March 2021 Colavita, Francesca Meschi, Silvia Gruber, Cesare Ernesto Maria Rueca, Martina Vairo, Francesco Matusali, Giulia Lapa, Daniele Giombini, Emanuela De Carli, Gabriella Spaziante, Martina Messina, Francesco Bonfiglio, Giulia Carletti, Fabrizio Lalle, Eleonora Fabeni, Lavinia Berno, Giulia Puro, Vincenzo Bartolini, Barbara Di Caro, Antonino Ippolito, Giuseppe Capobianchi, Maria Rosaria Castilletti, Concetta Front Med (Lausanne) Medicine BACKGROUND: Vaccines for coronavirus disease 2019 (COVID-19) are proving to be very effective in preventing severe illness; however, although rare, post-vaccine infections have been reported. The present study focuses on virological and serological features of 94 infections that occurred in Lazio Region (Central Italy) between 27 December 2020, and 30 March 2021, after one or two doses of mRNA BNT162b2 vaccine. METHODS: We evaluated clinical features, virological (viral load; viral infectiousness; genomic characterisation), and serological (anti-nucleoprotein Ig; anti-Spike RBD IgG; neutralising antibodies, nAb) characteristics of 94 post-vaccine infections at the time of diagnosis. Nasopharyngeal swabs (NPSs) and serum samples were collected in the framework of the surveillance activities on SARS-CoV-2 variants established in Lazio Region (Central Italy) and analysed at the National Institute for Infectious Diseases “L. Spallanzani” in Rome. RESULTS: The majority (92.6%) of the post-vaccine infections showed pauci/asymptomatic or mild clinical course, with symptoms and hospitalisation rate significantly less frequent in patients infected after full vaccination course as compared to patients who received a single dose vaccine. Although differences were not statistically significant, viral loads and isolation rates were lower in NPSs from patients infected after receiving two vaccine doses as compared to patients with one dose. Most cases (84%) had nAb in serum at the time of infection diagnosis, which is a sub-group of vaccinees, were found similarly able to neutralise Alpha and Gamma variants. Asymptomatic individuals showed higher nAb titres as compared to symptomatic cases (median titre: 1:120 vs. 1:40, respectively). Finally, the proportion of post-vaccine infections attributed either to Alpha and Gamma variants was similar to the proportion observed in the contemporary unvaccinated population in the Lazio region, and mutational analysis did not reveal enrichment of a defined set of Spike protein substitutions depending on the vaccination status. CONCLUSION: Our study conducted using real-life data, emphasised the importance of monitoring vaccine breakthrough infections, through the characterisation of virological, immunological, and clinical features associated with these events, in order to tune prevention measures in the next phase of the COVID-19 pandemic. Frontiers Media S.A. 2022-01-20 /pmc/articles/PMC8810639/ /pubmed/35127770 http://dx.doi.org/10.3389/fmed.2021.815870 Text en Copyright © 2022 Colavita, Meschi, Gruber, Rueca, Vairo, Matusali, Lapa, Giombini, De Carli, Spaziante, Messina, Bonfiglio, Carletti, Lalle, Fabeni, Berno, Puro, Bartolini, Di Caro, Ippolito, Capobianchi and Castilletti https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Colavita, Francesca Meschi, Silvia Gruber, Cesare Ernesto Maria Rueca, Martina Vairo, Francesco Matusali, Giulia Lapa, Daniele Giombini, Emanuela De Carli, Gabriella Spaziante, Martina Messina, Francesco Bonfiglio, Giulia Carletti, Fabrizio Lalle, Eleonora Fabeni, Lavinia Berno, Giulia Puro, Vincenzo Bartolini, Barbara Di Caro, Antonino Ippolito, Giuseppe Capobianchi, Maria Rosaria Castilletti, Concetta Virological and Serological Characterisation of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination Between December 2020 and March 2021 |
title | Virological and Serological Characterisation of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination Between December 2020 and March 2021 |
title_full | Virological and Serological Characterisation of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination Between December 2020 and March 2021 |
title_fullStr | Virological and Serological Characterisation of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination Between December 2020 and March 2021 |
title_full_unstemmed | Virological and Serological Characterisation of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination Between December 2020 and March 2021 |
title_short | Virological and Serological Characterisation of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination Between December 2020 and March 2021 |
title_sort | virological and serological characterisation of sars-cov-2 infections diagnosed after mrna bnt162b2 vaccination between december 2020 and march 2021 |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810639/ https://www.ncbi.nlm.nih.gov/pubmed/35127770 http://dx.doi.org/10.3389/fmed.2021.815870 |
work_keys_str_mv | AT colavitafrancesca virologicalandserologicalcharacterisationofsarscov2infectionsdiagnosedaftermrnabnt162b2vaccinationbetweendecember2020andmarch2021 AT meschisilvia virologicalandserologicalcharacterisationofsarscov2infectionsdiagnosedaftermrnabnt162b2vaccinationbetweendecember2020andmarch2021 AT grubercesareernestomaria virologicalandserologicalcharacterisationofsarscov2infectionsdiagnosedaftermrnabnt162b2vaccinationbetweendecember2020andmarch2021 AT ruecamartina virologicalandserologicalcharacterisationofsarscov2infectionsdiagnosedaftermrnabnt162b2vaccinationbetweendecember2020andmarch2021 AT vairofrancesco virologicalandserologicalcharacterisationofsarscov2infectionsdiagnosedaftermrnabnt162b2vaccinationbetweendecember2020andmarch2021 AT matusaligiulia virologicalandserologicalcharacterisationofsarscov2infectionsdiagnosedaftermrnabnt162b2vaccinationbetweendecember2020andmarch2021 AT lapadaniele virologicalandserologicalcharacterisationofsarscov2infectionsdiagnosedaftermrnabnt162b2vaccinationbetweendecember2020andmarch2021 AT giombiniemanuela virologicalandserologicalcharacterisationofsarscov2infectionsdiagnosedaftermrnabnt162b2vaccinationbetweendecember2020andmarch2021 AT decarligabriella virologicalandserologicalcharacterisationofsarscov2infectionsdiagnosedaftermrnabnt162b2vaccinationbetweendecember2020andmarch2021 AT spaziantemartina virologicalandserologicalcharacterisationofsarscov2infectionsdiagnosedaftermrnabnt162b2vaccinationbetweendecember2020andmarch2021 AT messinafrancesco virologicalandserologicalcharacterisationofsarscov2infectionsdiagnosedaftermrnabnt162b2vaccinationbetweendecember2020andmarch2021 AT bonfigliogiulia virologicalandserologicalcharacterisationofsarscov2infectionsdiagnosedaftermrnabnt162b2vaccinationbetweendecember2020andmarch2021 AT carlettifabrizio virologicalandserologicalcharacterisationofsarscov2infectionsdiagnosedaftermrnabnt162b2vaccinationbetweendecember2020andmarch2021 AT lalleeleonora virologicalandserologicalcharacterisationofsarscov2infectionsdiagnosedaftermrnabnt162b2vaccinationbetweendecember2020andmarch2021 AT fabenilavinia virologicalandserologicalcharacterisationofsarscov2infectionsdiagnosedaftermrnabnt162b2vaccinationbetweendecember2020andmarch2021 AT bernogiulia virologicalandserologicalcharacterisationofsarscov2infectionsdiagnosedaftermrnabnt162b2vaccinationbetweendecember2020andmarch2021 AT purovincenzo virologicalandserologicalcharacterisationofsarscov2infectionsdiagnosedaftermrnabnt162b2vaccinationbetweendecember2020andmarch2021 AT bartolinibarbara virologicalandserologicalcharacterisationofsarscov2infectionsdiagnosedaftermrnabnt162b2vaccinationbetweendecember2020andmarch2021 AT dicaroantonino virologicalandserologicalcharacterisationofsarscov2infectionsdiagnosedaftermrnabnt162b2vaccinationbetweendecember2020andmarch2021 AT ippolitogiuseppe virologicalandserologicalcharacterisationofsarscov2infectionsdiagnosedaftermrnabnt162b2vaccinationbetweendecember2020andmarch2021 AT capobianchimariarosaria virologicalandserologicalcharacterisationofsarscov2infectionsdiagnosedaftermrnabnt162b2vaccinationbetweendecember2020andmarch2021 AT castilletticoncetta virologicalandserologicalcharacterisationofsarscov2infectionsdiagnosedaftermrnabnt162b2vaccinationbetweendecember2020andmarch2021 |